Palantir Q3: Robust Profitability And AIP Growth; Maintain ‘Hold’ Rating (PLTR)

Michael Vi Palantir (NYSE:PLTR) reported both top-line and bottom-line beats in Q3 FY23, along with raised full-year guidance. I am encouraged by their profitability growth, achieving a 29.3% adjusted operating margin. I anticipate further margin expansion in the coming years. However, I don’t believe their operating margin can reach the levels of most typical software…

Read More

Axsome Update: Buy At Dips And Hold Forever (NASDAQ:AXSM)

PM Images Axsome Therapeutics (NASDAQ:AXSM) is increasingly poised to become the single most important player in the Major Depressive Disorder space, with its Auvelity tracking ahead of market expectations. In the last quarter, Auvelity sales were $27.6 million, representing 76% quarter-over-quarter growth. Being the first and only oral rapid acting NMDA receptor antagonist for MDD,…

Read More

VOXX International Stock: Upgrading On Gentex Corporation’s Strategic Investment – Hold

Ethan Miller Note: I have covered VOXX International Corporation (NASDAQ:VOXX) previously, so investors should view this as an update to my earlier articles on the company. Earlier this week, VOXX International Corporation or “VOXX” reported sequentially improved Q2/FY2024 results with increased gross margins and Adjusted EBITDA back to break-even levels. Regulatory Filings For the second…

Read More

MercadoLibre Stock: A Hold Given Current Valuation (NASDAQ:MELI)

Leila Melhado Investment Thesis In my view, MercadoLibre (NASDAQ:MELI) has effectively carved a niche for itself in Latin America’s e-commerce sector. As online commerce gains momentum in the region, MercadoLibre’s understanding of local nuances has positioned it ahead of many global competitors. However, when evaluating its investment potential, a measured approach is essential. A discounted…

Read More

Koninklijke Philips: Hold For Now (NYSE:PHG)

ljubaphoto Given our extensive coverage of Exor (OTCPK:EXXRF), today we decided to look at Koninklijke Philips NV (NYSE:PHG). In mid-August, Exor, the Agnelli Holding company, acquired a 15% equity stake in Philips for a total consideration of €2.6 billion. Looking at the press release, the investment holding company does not intend to purchase additional Philips…

Read More

NeuroSense: A Hold Ahead Of Phase 2b ALS Data (NASDAQ:NRSN)

Pornpak Khunatorn/iStock via Getty Images Thesis NeuroSense (NRSN) is a microcap focused on the treatment of neurodegenerative diseases. It is running a Phase 2b trial in 69 patients diagnosed with ALS, a fast-progressing neurodegenerative disease which is historically difficult to treat, with drug candidate PrimeC. Topline data of this trial are expected in Q4 2023….

Read More

Becton, Dickinson Stock Is A Hold, Here’s Why (NYSE:BDX)

pcess609 The Company Becton, Dickinson and Company (NYSE:BDX) is a $75-billion market cap global healthcare company that specializes in developing, manufacturing, and selling a wide range of medical supplies, devices, laboratory equipment, and diagnostic products. They serve healthcare institutions, physicians, researchers, clinical laboratories, the pharmaceutical industry, and the general public worldwide. According to the latest…

Read More

Converge Technology Solutions: On Hold Pending Confirmatory Data Points (TSX:CTS:CA)

da-kuk Summary Converge Technology Solutions (TSX:CTS:CA) is an information technology services provider, providing integrated hardware and software solutions to mid-market enterprises. The majority of its revenue is generated from value added reselling of hardware and software solutions, with the remainder coming from professional services. CTS has achieved most of its incredible growth through acquisitions, but…

Read More

TIP: US Stocks Hold The Key To Real Yields

JamesBrey I continue to buy the dips in the iShares TIPS Bond ETF (NYSEARCA:TIP) which now has a real yield to maturity of 2.6% before fees. This yield is completely at odds with the real economy, where slowing growth and high and rising government debt and deficits suggest real borrowing costs should be below zero….

Read More

McDonald’s: The Growth Story Suggests A Hold (NYSE:MCD)

M. Suhail The McDonald’s Corporation (NYSE:MCD) has demonstrated a robust history of consistent earnings growth, solidifying its position as a stalwart in the fast-food industry. This sales growth has persisted in recent quarters, with strong sales growth reported across most of McDonald’s major markets. This impressive performance is attributed in part to strategic price adjustments…

Read More

Compass Minerals: Dividend Doesn’t Offset Lack Of Economic Value, Rate Hold (NYSE:CMP)

Pgiam/iStock via Getty Images Investment briefing No relief for Compass Minerals International, Inc. (NYSE:CMP)’s shareholders leading into the back end of the year, with the company’s equity stock attracting offers at 2-year lows as I write (Figure 1). As a reminder, CMP produces essential minerals, namely salt, sulfate of potash and specialty fertilizers. Its core…

Read More

Bally’s: Asset-Heavy Business With Large Capital Requirements, Rate Hold (NYSE:BALY)

naphtalina/iStock via Getty Images Investment Summary Casino and gaming majors offer compounding factors with interesting economics, provided the business returns stack up on capital employed into operations. Bally’s Corporation (NYSE:BALY) does not meet these requirements in my view. The company has piled investment to grow operations with minimal earnings to show for this. Sure, revenues,…

Read More

Zurn Elkay Water Solutions: Growth Not Accretive To Shareholder Value, Hold (ZWS)

naphtalina/iStock via Getty Images Investment summary Zurn Elkay Water Solutions Corporation (NYSE:ZWS) has exhibited positive growth trends across 2023 following its Elkay acquisition last year. Deeper analysis reveals the economics on this growth hasn’t necessarily added shareholder value. ZWS is a water management pure-play. It boasts an extensive product portfolio with offerings in water safety…

Read More

Vericel Stock: A Knee-Jerk ‘Hold’ Worth Its Salt (NASDAQ:VCEL)

Moyo Studio/E+ via Getty Images Introduction Founded in 1989, Michigan-based Vericel (NASDAQ:VCEL) is a commercial-stage biopharmaceutical leader specializing in advanced therapies for sports medicine and severe burn care. It markets three FDA-approved products in the U.S.: MACI for knee cartilage defects, Epicel for extensive burns, and recently approved NexoBrid for eschar removal in thermal burns….

Read More

Alvotech: FDA Overhang Remains, Remaining Constructive, Initiate Hold (NASDAQ:ALVO)

Matteo Colombo Investment briefing The biosimilars drug market is forecast to expand at a geometric growth rate of ~18% from 2023—2028, garnishing immense capital inflows along the way. Alvotech (NASDAQ:ALVO) is firmly positioned within the biosimilars value chain and has the potential to unlock compelling value should it successfully convert its pipeline assets. To date,…

Read More